Category | Top 50 Pharma

Johnson & Johnson: Company profile

Posted on 27 June 2013

Johnson & Johnson, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Endo Pharmaceuticals: Company profile

Posted on 26 June 2013

Endo Pharmaceuticals, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Galderma: Company profile

Posted on 26 June 2013

Galderma, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Grifols: Company profile

Posted on 26 June 2013

Grifols, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Shionogi: Company Profile

Posted on 26 June 2013

Shionogi, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Hospira: Company Profile

Posted on 26 June 2013

Hospira, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Kyowa Hakko Kirin: Company Profile

Posted on 18 June 2013

Kyowa Hakko Kirin, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Warner Chilcott: Company Profile

Posted on 18 June 2013

Warner Chilcott, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Boehringer Ingelheim: Company Profile

Posted on 14 June 2013

Boehringer Ingelheim, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,

Lundbeck: Company Profile

Posted on 14 June 2013

Lundbeck, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Tags: ,